<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03972644</url>
  </required_header>
  <id_info>
    <org_study_id>S-20190006</org_study_id>
    <nct_id>NCT03972644</nct_id>
  </id_info>
  <brief_title>Danish National Randomized Study on Early Aortic Valve Replacement in Patients With Asymptomatic Severe Aortic Stenosis</brief_title>
  <acronym>DANAVR</acronym>
  <official_title>Danish National Randomized Study on Early Aortic Valve Replacement in Patients With Asymptomatic Severe Aortic Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aalborg University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zealand University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the impact of early surgery in patients with&#xD;
      asymptomatic severe aortic valve stenosis with signs of subclinical LV dysfunction despite&#xD;
      preserved LVEF, with a watchfull waiting approach.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Since the seminal paper by Ross and Braunwald, the development of symptoms has been regarded&#xD;
      as one of the most important precursors of a poor outcome in aortic stenosis (AS), and is&#xD;
      today half a century later, still the leading reason for referral for aortic valve&#xD;
      replacement (AVR). The development of symptoms is however often preceded by structural&#xD;
      changes in the left ventricle (LV).These changes including concentric remodeling and LV&#xD;
      hypertrophy have been regarded as compensative measures to adapt the LV to increased&#xD;
      ventricular afterload. Although LV hypertrophy may preserve wall-stress in the normal range&#xD;
      and increase contractility allowing the preservation of stroke volume, this occurs at the&#xD;
      expense of increased filling pressures. Diastolic dysfunction with increased filling pressure&#xD;
      lead to left atrial (LA) dilatation and significantly contributes to the development of&#xD;
      symptoms.&#xD;
&#xD;
      Despite successful surgery, AS patients have increased long-term mortality and morbidity&#xD;
      compared to the general population, and the outcome is largely determined by the degree of&#xD;
      preoperative structural LV and LA alterations. This has led to the theory that AVR prior to&#xD;
      the development of symptoms could improve outcome, a view supported by prospective and&#xD;
      retrospective studies.These studies were however small, with some important limitations. In&#xD;
      addition, there has been a concern that operative risk and prosthetic valve related long-term&#xD;
      morbidity and mortality does not justify surgery on every asymptomatic patient with severe&#xD;
      AS. Numerous studies have suggested that markers of LV structure and function, particularly&#xD;
      LA volume index,E/e' and brain natriuretic peptides (BNP) all reflecting LV filling pressures&#xD;
      may identify patients with benefit of early AVR. Accordingly, the most recent European&#xD;
      guideline for management of valvular disease has implemented BNP as a class IIa&#xD;
      recommendation for AVR in asymptomatic AS patients,although no randomized studies have&#xD;
      demonstrated that early surgery based on these markers improve prognosis.&#xD;
&#xD;
      The purpose of this study is thus to evaluate if early AVR in patients with signs of elevated&#xD;
      LV filling pressuresmay improve long-term outcome in patients with asymptomatic severe AS,&#xD;
      compared to conventional symptom-guided surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2029</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2029</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>all-cause mortality</measure>
    <time_frame>After 379 events (approx 5 years)</time_frame>
    <description>All-cause mortality assessed by Danish patient records</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Combined endpoint</measure>
    <time_frame>After 379 events (approx 5 years)</time_frame>
    <description>All-cause mortality + hospitalization due to heart failure and stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all-cause mortality in patients with low-gradient AS</measure>
    <time_frame>After 379 events (approx 5 years)</time_frame>
    <description>All-cause mortality in patients with meangradient &lt;40 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined endpoint in low-gradient AS</measure>
    <time_frame>After 379 events (approx 5 years)</time_frame>
    <description>All-cause mortality + hospitalization to heart failure and stroke when MG&lt;40 mmHg</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pericardiocentesis</measure>
    <time_frame>5 years</time_frame>
    <description>Need of pericariocentesis</description>
  </other_outcome>
  <other_outcome>
    <measure>sternal infection</measure>
    <time_frame>5 years</time_frame>
    <description>hospitalization due to sternal infection</description>
  </other_outcome>
  <other_outcome>
    <measure>Persistent renal failure</measure>
    <time_frame>5 years</time_frame>
    <description>complete loss of renal function exceeding 4 weeks.</description>
  </other_outcome>
  <other_outcome>
    <measure>endocarditis</measure>
    <time_frame>5-years</time_frame>
    <description>hospitalization due to endocarditis</description>
  </other_outcome>
  <other_outcome>
    <measure>major bleeding</measure>
    <time_frame>5 years</time_frame>
    <description>intracerebral bleeding or bleeding resulting in substantial hemodynamic compromise requiring treatment instability</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1700</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Diastolic Dysfunction</condition>
  <arm_group>
    <arm_group_label>Early intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will undergo aortic valve replacement immediately</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Watchfull waiting</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will be followed and treated as recommended by guidelines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Aortic valve replacement</intervention_name>
    <description>Open heart surgery or transcatheter surgery</description>
    <arm_group_label>Early intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Severe AS defined as&#xD;
&#xD;
               1. aortic valve area (AVA) ≤1 cm2, AND&#xD;
&#xD;
               2. Transvalvular maximum velocity (Vmax) ≥3.5 m/s AND&#xD;
&#xD;
               3. AS severity evaluated severe by a heart valve team conference. In cases where&#xD;
                  severity is not unambiguous an integrative approach will be utilized combining&#xD;
                  echocardiographic markers of valve severity and LV function, and if necessary&#xD;
                  aortic valve calcification estimated by non-contrast CT.&#xD;
&#xD;
                  2. Considered to be asymptomatic (estimated by a consultant in cardiology) 3.&#xD;
                  Considered to be candidate for AVR (transcatheter AVR/surgical AVR) 4. Sign of&#xD;
                  increased LV filling pressures18 or reduced longitudinal LV systolic function&#xD;
&#xD;
               1. Left atrial volume index (LAVi) &gt; 34 ml/m2; OR&#xD;
&#xD;
               2. ratio of early diastolic peak mitral inflow velocity (E) to early mitral annulus&#xD;
                  diastolic velocity (e') ratio E/e'avg&gt;13; OR&#xD;
&#xD;
               3. Threefold elevation in NT-proBNP compared to the upper expected age and gender&#xD;
                  value. OR&#xD;
&#xD;
               4. GLS&gt;-15 5. Age ≥18 years 6. Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. LVEF&lt;50%&#xD;
&#xD;
          2. Very severe AS defined as Vmax&gt;5 m/s.&#xD;
&#xD;
          3. Concomitant severe valvular disease other than AS&#xD;
&#xD;
          4. Previous valvular surgery&#xD;
&#xD;
          5. Estimated glomerular filtration rate&lt;30 ml/min/m2&#xD;
&#xD;
          6. Dementia&#xD;
&#xD;
          7. Women of childbearing potential&#xD;
&#xD;
          8. Inability to provide informed consent&#xD;
&#xD;
          9. Age&gt;85 years.&#xD;
&#xD;
         10. Supravalvular or subvalvular AS&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jordi S Dahl, MD, PhD</last_name>
    <phone>+4523823016</phone>
    <email>jordi.dahl@rsyd.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jacob E Møller, MD, PhD</last_name>
    <email>jem@dadlnet.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <state>Fyn</state>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordi S Dahl, MD, Ph.D</last_name>
      <phone>23823016</phone>
      <email>jordi.dahl@rsyd.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 31, 2019</study_first_submitted>
  <study_first_submitted_qc>May 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2019</study_first_posted>
  <last_update_submitted>September 9, 2020</last_update_submitted>
  <last_update_submitted_qc>September 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Jordi Dahl</investigator_full_name>
    <investigator_title>Associate Professor, MD, Ph.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

